Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Rush Street Interactive Inc (RSI) vs Sanofi SA (SNY) Price & Performance

Rush Street Interactive IncTrade

Price performance (Past 24H)

Key statistics

Rush Street Interactive Inc vs Sanofi SA — how do they compare? Rush Street Interactive Inc trades at $26.65 (market cap $3.12B), while Sanofi SA trades at $43.12 (market cap $104.06B). The key difference: Sanofi SA is far larger — about 33.4× Rush Street Interactive Inc's market cap, and Sanofi SA pays a 5.61% dividend while Rush Street Interactive Inc pays none. Which is the better fit depends on your goals.

RSISNY
Market Cap
$3.12B$104.06B
Sector
TechnologyHealth
52-Week High
$34.52$52.34
52-Week Low
$15.89$41.33
Enterprise Value
$2.79B$124.09B
Dividend Yield
5.61%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Rush Street Interactive Inc

Rush Street Interactive (RSI) trades at $27.02, up 1.27% today, with a bullish technical signal from moving averages and strong institutional interest. Recent Q2 2026 results showed record revenue of $393.8 million and net income of $29.3 million, beating EPS expectations. The company raised full-year 2026 guidance, reflecting robust growth in online casino and sports betting markets. Analyst consensus is strongly bullish with a $34.75 price target, indicating 29% upside potential from current levels.

The outlook for RSI is positive, driven by accelerating revenue growth and expanding market share, but risks include intense competition and regulatory scrutiny in the gambling sector. High valuation multiples like a P/E of 87.16 suggest elevated expectations, requiring continued execution. Institutional buying, such as BlackRock's $448 million investment in Q2 2026, supports confidence, though investors should monitor margin pressures from rising marketing costs.

Sanofi SA

SNY trades at $43.16, down 2.45% today, with a bearish technical signal from moving averages but bullish oscillators. The company reported Q2 2026 EPS of $1.21, beating expectations, and raised its 2026 outlook driven by Dupixent strength. Financials show improved net income of $7.81B in 2025, with a P/E of 22.94 and net margin of 8.09%.

Outlook is mixed: strong drug performance and analyst hold ratings suggest stability, but pipeline setbacks and projected 2026 profit margin decline to 8.09% pose risks. The stock offers a 5.4% dividend yield, trading below sector P/E, presenting value if growth execution offsets challenges.

Returns comparison

Trailing returns across standard periods

About Rush Street Interactive Inc

Rush Street Interactive, Inc. is a digital gaming and sports betting company operating in the regulated U.S. and international markets. The company owns and operates online casino (iGaming) and sports wagering platforms, including BetRivers and PlaySugarHouse brands. RSI focuses on providing a secure and high-quality online gaming experience, leveraging its proprietary technology platform and commitment to responsible gaming.

Read more on RSI

About Sanofi SA

Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.

Read more on SNY